FDA approves third-trimester vaccine to prevent pertussis in infants younger than 2 months

The FDA announced it approved a vaccine administered during the third trimester of pregnancy to prevent pertussis — whooping cough — in infants younger than 2 months of age.
When the vaccine (Boostrix, GlaxoSmithKline Biologicals) is administered, it boosts antibodies in the pregnant mother, which are transferred to the developing baby, according to a press release from the FDA.
“Pertussis disease is a highly contagious respiratory illness affecting all age groups. However, babies are at highest risk for getting pertussis and having serious complications from it,” Peter

The FDA announced it approved a vaccine administered during the third trimester of pregnancy to prevent pertussis — whooping cough — in infants younger than 2 months of age.
When the vaccine (Boostrix, GlaxoSmithKline Biologicals) is administered, it boosts antibodies in the pregnant mother, which are transferred to the developing baby, according to a press release from the FDA.
“Pertussis disease is a highly contagious respiratory illness affecting all age groups. However, babies are at highest risk for getting pertussis and having serious complications from it,” Peter